Paclitaxel 300mg/50mL
Product Overview
| Generic Name | Paclitaxel 300mg/50mL |
| Brand Name(s) | Taxol, Pacliltax, Nanoxel, Z-Taxel, Altaxel, Plaxel |
| Category | Antineoplastic / Cancer |
| Form | Concentrate for infusion (vial) |
| Strength | 300 mg/50 mL (6 mg/mL |
| Therapeutic Class | Microtubule inhibitor (taxane class) |
| ATC Code | L01CD01 |
Manufacturing & Regulatory
| Manufacturer | Fresenius Kabi (Nanoxel), Aetos, Biogen, Cipla |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Manufacturer-specific, not public |
| COFEPRIS | 010.000.5435.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 Vials |
| Shelf Life | 24 Months |
| Storage | Store below 25 °C, protect from light |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 10 Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Certificate of Analysis likely provided on purchase; not publicly posted |
| SDS-Safety Data Sheet (PDF) | Upon Request, not publicly posted |
| CTD Summary (PDF) | proprietary; may be available upon commercial commitment/documentation fee |
Special Notes
Indications & Usage: Paclitaxel is indicated—often with platinum chemotherapy—for treatment of ovarian, breast, lung (NSCLC), pancreatic cancers, Kaposi's sarcoma, cervical cancer . It stabilizes microtubules to inhibit cell division. Pre‑medication with corticosteroids, antihistamines, H2 antagonists is required due to hypersensitivity risk